AR and prostate adenocarcinoma: Although ADT initially suppresses tumor growth by targeting androgen receptor (AR) signaling, a significant proportion of prostate adenocarcinomas (AdPC) develop resistance to ADT, progressing to castration-resistant prostate cancer (CRPC).